Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.

Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20; 27(33):5506-12.

View in: PubMed

subject areas

Adenocarcinoma
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Camptothecin
Cisplatin
Confidence Intervals
Deoxycytidine
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Infusions, Intravenous
Kaplan-Meier Estimate
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Staging
Pancreatic Neoplasms
Risk Assessment
Survival Analysis
Taxoids
Treatment Outcome
United States

authors with profiles

Hedy Kindler